Contact Us

Use the form on the right to contact us.

4955 Directors Place
San Diego, CA, 92121
United States

8582034200

The ADC Specialty Company

News

November 12-15, 2018, San Diego, USA

9th World ADC San Diego

Levena returns to World ADC Summit for 7 consecutive years with a full panels of ADC specialized experts. We will have Directors of Conjugation Service, Chemistry, Analytical, Cancer Research, and CMC available for discussion to answer all your questions. To make an appointment, please email us info@levenabiopharma.com. Join us at our booth for additional information.


June 27-28, 2018, Shanghai Pudong, China

Introducing world leading Antibody-Drug Conjugate (ADC) conference to Asia

Levena Biopharma expands its collaboration with Hanson Wade. After successful collaborations at the US and Europe ADC Summits, Levena Biopharma is now the Lead Sponsor of the 1st World ADC Asia Summit.

To schedule meetings, please contact:

info@levenabiopharma.com.


Levena Biopharma’s Partner BioAtla Announces FDA clearance of Its Investigational New Drug Application for CAB-AXL-ADC Therapeutic

 

SAN DIEGO, Jan. 24, 2018 – Levena Biopharma’s partner, BioAtla, LLC, a global biotechnology company focused on the development of Conditionally Active Biologic (CAB) protein therapeutics, announced today the U.S. Food and Drug Administration (FDA) has cleared BioAtla's Investigational New Drug application (IND) for BA3011, a novel conditionally active AXL-targeted antibody-drug conjugate (CAB-AXL-ADC), in patients with solid tumors. Under this IND, the company intends to initiate a first-in-human, open label, multicenter, dose escalation and dose expansion study of CAB-AXL-ADC in patients with locally advanced or metastatic solid tumors. CAB-AXL-ADC will be BioAtla's first CAB investigational product to enter clinical trials in the United States.

Levena Biopharma has collaborated with BioAtla in its ADC product development area over the past few years and provided process development and GMP production of linker-toxin to support the IND filing of BA3011 program. Since the inception of Levena’s GMP facility in Suzhou, China, the company has supported IND filing of novel ADC therapies in US, China and Korea.

About BioAtla, LLC
BioAtla is a global biotechnology company with operations in San Diego, California, and Beijing, China. BioAtla develops novel monoclonal antibody and other protein therapeutic product candidates designed to have more selective targeting, greater efficacy, and more cost-efficient and predictable manufacturing than traditional antibodies.

About Levena Biopharma, Co., Ltd.

Levena Biopharma Co., Ltd., established in 2013, is a biotechnology company dedicated to enable novel antibody-drug conjugate (ADC) therapeutic development. The company offers partners site-specific conjugation technology (K-LOCK and C-LOCK) and novel proprietary linker toxin. Levena Biopharma currently operates in its research and manufacturing facilities in Suzhou, Nanjing and San Diego with capabilities from ADC discovery research, process/analytical development to GMP production of linker-toxin and ADC conjugate.


March 26-28, 2018 | Berlin, Germany

Levena Biopharma is exhibiting at the 8th World ADC Berlin Conference.

To schedule a personal meeting please contact info@levenabiopharma.com.

ADC-Berlin-Web.png

Levena Biopharma Supplies GMP Linker-Toxin for Alteogen’s Her-2 ADC Program

 

November 30, 2017

Suzhou and Daejeon, November 30, 2017-- Levena Biopharma Co. Ltd., today announced a supply agreement with Alteogen, a public traded biotechnology company based in South Korea, to support the development of its leading antibody drug conjugate (ADC) product ALT-P7.

In August 2017, Alteogen announced its plan to start phase I clinical trial of ALT-P7, an ADC product utilizing Alteogen’s proprietary NextMabTM ADC technology, in patients with HER-2 positive breast cancer. Under this agreement, Levena Biopharma will provide GMP grade of linker-toxin for Alteogen’s clinical program. Levena Biopharma completed its GMP facility in 2017 and this is its first GMP supply agreement with a Korean partner. Earlier in 2017, Levena has supported partners in China and US for their linker-toxin GMP production.

About Alteogen Inc

Alteogen Inc. is a biopharmaceutical company devoted to develop the next generation long-acting biobetters which have properties of the increased in-vivo half life. ALTEOGEN is also developing monoclonal antibody biobetter with ALTEOGEN’s proprietary ADC (Antibody Drug Conjugate) technology and monoclonal antibody biosimilars with blockbuster market potential.

Based on excellent and experienced R&D professionals and our own original biotechnologies, ALTEOGEN is focusing on developing and marketing biobetters and biosimilars by partnership with global pharmaceutical companies.

About Levena Biopharma, Co., Ltd.

Levena Biopharma Co., Ltd., established in 2013, is a biotechnology company dedicated to enable novel antibody-drug conjugate (ADC) therapeutic development. The company offers partners site-specific conjugation technology (K-LOCK and C-LOCK) and novel proprietary linker toxin. Levena Biopharma currently operates in its research and manufacturing facilities in Suzhou, Nanjing and San Diego with capabilities from ADC discovery research, process/analytical development to GMP production of linker-toxin and ADC conjugate.


September 20 – 22, 2017 | San Diego, CA

Levena Biopharma is the proud senior partner at the 8th World ADC Conference.

To schedule a personal meeting please contact info@levenabiopharma.com.

SPEX-email-badge.png


Openning of cGMP Facility in Suzhou, China

SAN DIEGO, May 2, 2017 /PRNewswire/ -- LevenaBiopharma (Levena), is a subsidiary of Sorrento Therapeutics, Inc. (NASDAQ: SRNE; "Sorrento"). Levana has three sites locations in San Diego, Suzhou, and Nanjing China. It announced today a recently completed construction project in Suzhou has finished the first phase of the new cGMP production facility with the release of a cGMP API. The second phase of this construction project will add an additional 24.5 K sq ft is to be completed in Q4 2017. This new state of art facility will provide the much needed expertise and resources for our domestic and international partners. Management expect to realize significant revenues utilizing the capacities and capabilities as a CRO/CMO in the development and commercial productions of Antibody Drug Conjugates by 2020.